Novo Nordisk · 15 hours ago
Internship - Scientific Publications
Plainsboro, NJ
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company dedicated to improving patients' quality of life. The Scientific Publications intern will focus on medical writing activities and metrics gathering to support the publications team's strategic objectives, including drafting scientific content and analyzing publication metrics.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Drafting and editing scientific content for congress abstracts and posters under senior author supervision, ensuring adherence to journal guidelines and Good Publication Practice (GPP) standards
Collecting and analyzing publication metrics, including citation tracking, journal impact factors, manuscript acceptance rates, and congress presentation reach, to inform future publication strategies and demonstrate scientific impact
Maintaining publication tracking databases and supporting quality control processes throughout the publication lifecycle
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than May 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress doctoral degree in Medicine, Biomedical, Pharmacy, Pharmaceutical Sciences or a related discipline
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase